Cannabis Bioscience Delays Quarterly Report as Annual Audit Remains Incomplete

PUBT · 1d ago
Cannabis Bioscience Delays Quarterly Report as Annual Audit Remains Incomplete
  • Cannabis Bioscience International Holdings delayed its Form 10-Q for the quarter ended August 31, 2026, because financial information could not be completed.
  • The fiscal year ended May 31, 2026, audit remains unfinished, preventing completion of quarterly statements; the annual report also remains unfiled.
  • Filing within the five-day extension period is not assured.
  • Quarterly revenue is expected at approximately $1,000 versus $24,200 a year earlier, reflecting the clinical-trial business’s July 31, 2026, termination.
  • Net loss is projected at approximately $172,000 versus $82,645 a year earlier, reflecting higher compensation costs, increased interest expense and absent derivative-related gains.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007933), on October 16, 2026, and is solely responsible for the information contained therein.